$DCOY News

Decoy Therapeutics Files Prospectus Related To The Resale Of Up To 2,368,868 Common Shares

Decoy Therapeutics to Present at The Small Cap Showcase

Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program

Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release

/C O R R E C T I O N -- Decoy Therapeutics, Inc/

Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules

Decoy Therapeutics To Exercise 1,184,434 Series B Warrants At $3.25/Share for ~$3.85M; Cuts Series A & C Warrant Prices To $3.25 And Issues 2,368,868 New Warrants At $3.25/Share

Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding

Decoy Therapeutics Announces Its Exploring Non-Dilutive Federal Grants, Public Health Collaborations To Support Preclinical, Clinical Development Of Biodefense Pipeline

Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Decoy Therapeutics Announces The Expansion Of Its Intellectual Property Portfolio, Which Now Comprises Seven Patent Families

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Decoy Therapeutics Announces That One Of Its D-MAV Candidates Demonstrates In Vitro Activity Against Wild-Type Ebola Zaire Virus

Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors

Decoy Therapeutics Files Prospectus For Offering 3.767M Common Shares On Behalf Of Common Shareholders

DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally?

Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London